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Abstract Different classes of protein kinase inhibitors for
protein kinase C, cAMP-dependent protein kinase or protein
tyrosine kinases have been studied for their effect on phospho-
lipid metabolism. The results show that among the compounds
studied, only 4P-aminohydroxyflavone (AHF), previously de-
scribed as a specific inhibitor of the protein tyrosine kinase
p56lck, markedly increased phosphatidylserine synthesis in
Jurkat T cells. The biosyntheses of phosphatidylcholine and
phosphatidylethanolamine were not affected. Also, the synthesis
of phospholipids from tritium-labeled fatty acid as precursor was
left unchanged by the p56lck inhibitor. The decreased phospha-
tidylserine synthesis induced when triggering the CD3-TCR
complex was impaired by AHF, suggesting that p56lck could be
implicated in the regulation of the serine-base exchange enzyme
system. Direct evidence for the participation of p56lck in the
regulation of the serine-base exchange enzyme system was
obtained by using p56lck-deficient Jurkat cells (J.CaM 1.6) in
which the basal base exchange activity was markedly increased
and on the other hand AHF had no effect. In addition,
transfection of J.Cam 1.6 cells with p56lck-cDNA allowed
recovery of the AHF activity.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
The phospholipid base exchange enzyme system that cata-
lyzes incorporation of exogenous choline, ethanolamine and
serine into phospholipids involves separate enzymes speci¢c
for each polar head group of phospholipids. In the past
5 years, evidence accumulated demonstrating that the phos-
pholipid base exchange activity is regulated upon membrane
receptor triggering in di¡erent cell lines. In rat liver plasma
membrane, phospholipid base exchange activity is regulated
by G-proteins and P2y-purinergic receptor [1], in the neuro-
blastoma cell line LA-N-1, the serine-base exchange activity is
modulated by muscarinic receptors [2]. In glioma C6 cells, the
serine-base exchange is inhibited by glutamate and acetylcho-
line [3]. We have previously shown that in T cell lines trigger-
ing the T cell receptor complex induces a rapid and sustained
decrease of phosphatidylserine (PtdSer) synthesis [4,5]. PtdSer
synthesis in mammalian cells occurs only through the serine-
base exchange enzyme system. The enzyme is located on the
membrane of the endoplasmic reticulum [6,7] and its activity
is maintained by the high Ca
2
concentration existing in the
endoplasmic reticulum in non-activated cells. Upon activation
of lymphocytes with CD3 mAb or activation of glioma C6
cells with acetylcholine or glutamate, Ca
2
ions are released
into the cytoplasm and it is accepted that decreasing the Ca
2
concentration in the endoplasmic reticulum results in de-
creased activity of the serine-base exchange enzyme and re-
duced PtdSer biosynthesis. This was con¢rmed by the fact
that thapsigargin, a blocker of the endoplasmic reticulum
Ca
2
-ATPase and Ca
2
ionophores induce a strong decrease
of PtdSer synthesis [3,5,8]. On these experimental bases, we
have repeatedly used the measure of PtdSer synthesis as a tool
to follow Jurkat T cell activation [9^11].
Little is known about the eventual regulation of the serine-
base exchange activity by protein kinases; a possible involve-
ment of PKC has been suggested since, in HL60 cells, phorbol
ester inhibits PtdSer synthesis [12] but this was not the case in
Jurkat T cells [4]. The participation of PKA has also been
suggested from experiments performed in an acellular system
[13].
It is generally accepted that T cell activation starts with the
phosphorylation on tyrosine residues of several proteins.
Among these proteins several protein tyrosine kinases have
been characterized such as p59
fyn
, ZAP-70 and p56
lck
that
play a major role in T cell activation [14^16]. The tyrosine
kinase pathway, is linked to the Ca
2
pathway through the
phosphorylation on tyrosine residue of phospholipase CQ1.
This phospholipase activated by phosphorylation hydrolyses
phosphatidylinositol bisphosphate into the two second mes-
sengers diacylglycerol, a protein kinase C activator and inosi-
tol trisphosphate that liberates Ca
2
from the endoplasmic
reticulum. On these bases, it was imaginable to link the
CD3-induced decrease of PtdSer synthesis to one kinase in-
volved in the tyrosine kinase pathway. p56lck is a central
kinase in the activation schemas of T cells. 4-Aminohydroxy-
£avone (AHF) a speci¢c inhibitor of this kinase has been
recently developed [17]. We show here by using AHF and
J.Cam 1.6 p56lck-de¢cient cells, that p56lck participates in
the regulation of the serine-base exchange enzyme.
2. Materials and methods
2.1. Cells
The human T cell line Jurkat kindly supplied by Dr. A.M. Schmitt-
Verhulst (Centre d'Immunologie, Marseille-Luminy, France) was
cloned by limiting dilution. Clone D (JD) was selected on the basis
of its interleukin 2 (IL-2) production when activated with phytohe-
magglutinin and the phorbol ester PMA. The Jurkat clone E6-1 was
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purchased from ATCC (ATCC TIB 152). The Jurkat mutant defective
in p56
lck
kinase, J.CaM1.6, derived from JE6-1 were also purchased
from ATCC (ATCC CRL-2063). Cells were cultured in RPMI 1640
(Gibco, Cergy-Pontoise, France) supplemented with 5% fetal calf se-
rum (Biowhitaker, Fontenay, France), 50 units/ml penicillin, 50 Wg/ml
streptomycin, 2 mM L-glutamine, 1 mM pyruvate.
2.2. Monoclonal antibodies
The CD3 monoclonal antibody, X35, was puri¢ed from ascites
gifted by Dr. D. Bourel (CTS Lille, France).
2.3. Phospholipid synthesis in Jurkat cells
Jurkat cells (2U10
6
) were maintained in 0.5 ml of a bu¡er (pH 7.4)
containing 137 mM NaCl, 2.7 mM KCl, 2.5 mM glucose, 20 mM
HEPES, 1 mM MgCl
2
and 1 mM CaCl
2
at 37³C in the presence of
either 4 WCi of [
3
H]serine, [
3
H]choline or [
3
H]ethanolamine or 2 WCi
[
3
H]arachidonic acid and e¡ectors (see concentrations in the ¢gure
legends). After an incubation period varying from 0 to 2 h the cells
were rapidly sedimented in an Eppendorf centrifuge, the supernatants
were discarded, and cell phospholipids were extracted using chloro-
form/methanol according to Bligh and Dyer [18]. This two-step ex-
traction procedure allowed the determination of
3
H-labeled products
incorporated into the cells by measuring a 25 ml sample of the chloro-
form/methanol extract. Then the addition of chloroform and water
allowed the separation of the organic and aqueous phases. The lipid
extracts (organic phases) were analysed by thin-layer chromatography
on LK6D chromatography plates (Wathman) in a solvent system
composed of chloroform/methanol/acetic acid/water (75:45:12:3). Au-
thentic phospholipid standards (Sigma) were run in parallel and de-
tected with iodide vapor. Radioactivity in lipid spots was determined
by using an automatic linear radiochromatography analyser, Trace-
master 20 (Berthold) equipped with an 8 mm window and the inte-
gration software supplied by the manufacturer.
2.4. Transfection of J.CaM 1.6 cells
J.CaM 1.6 cells were transfected via electroporation by using p56lck
cDNA included in the mammalian expression vector pEF-BOS [19,20]
The vector was a generous gift from Dr. A.C. Carrera (Centro Na-
cional Biotecnologia, Universidad Autonoma Campus de Cantoblan-
co, Madrid, Spain). p56lck positive cells were cloned by limiting di-
lutions. The presence of p56lck was veri¢ed by Western blots of cells
extracts with anti-p56lck mAbs. Anti-lck mAbs were purchased from
UpstateBiotechnology (Lake Placid, USA).
3. Results and discussion
3.1. E¡ect of AHF on phospholipid synthesis
We ¢rst studied PtdSer synthesis in a Jurkat T cell clone
(JD), in the presence of di¡erent concentrations of AHF, a
compound designed as a speci¢c p56lck inhibitor [17]. The
results (Fig. 1A) show that this compound strongly increased
PtdSer synthesis with an EC
50
=20 WM. Kinetic analysis
showed that PtdSer synthesis was increased very early, 6 15
min after AHF treatment (Fig. 1B). The total incorporation
of [
3
H]serine by cells remained unchanged, indicating that
AHF does not modify the transport of the amino acid
through the membrane (not shown). The action of AHF ap-
peared highly speci¢c for PtdSer since the biosynthesis of
phosphatidylcholine (PtdCho) and phosphatidylethanolamine
(PtdEtn) monitored by measuring the amount of [
3
H]choline
and [
3
H]ethanolamine incorporated into phospholipids was
not a¡ected by the drug (Table 1). Moreover, the incorpora-
tion of [
3
H]palmitic acid into phospholipids (Table 1) and the
formation of PtdEtn from decarboxylation of PtdSer were not
a¡ected by AHF (Fig. 1C). The elevation in PtdEtn shown in
Fig. 1C parallels the increase in PtdSer synthesis, indicating
that the decarboxylation pathway remains active during AHF
treatment.
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Fig. 1. E¡ect of AHF on phosphatidylserine synthesis. Jurkat cells,
clone D, were incubated at 37³C in the presence of [
3
H]serine for
120 min in the presence of varying concentrations of AHF. Phos-
pholipids were extracted and analysed by thin-layer chromatogra-
phy. The radioactivity incorporated into PtdSer was quanti¢ed and
plotted against AHF concentrations (A). (B) Cells were incubated
with [
3
H]serine without (a) or with 40 WM AHF (b) for di¡erent
periods of time. (C) Incorporation of [
3
H]serine into PtdEtn
through the PtdSer-decarboxylation pathway in control (E) and 40
WM AHF (F) treated cells. The ¢gure shows an experiment repre-
sentative of three others.
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3.2. Speci¢city of AHF
Di¡erent protein kinase inhibitors were then used to test the
speci¢city of AHF. Among these inhibitors, H7 and H8 acting
on protein kinase A, protein kinase C and protein kinase G
according to the concentration used were unable to modify
PtdSer synthesis even at 100 WM. Tyrosine protein kinase
inhibitors such as Compound 5, lavendustin, genistein, tyr-
phostin A9, A23 and A49 were also inactive on the serine-
base exchange system at concentrations varying between 0.1
and 100 WM. Only staurosporine, a non-speci¢c inhibitor of
many tyrosine protein kinases, including p56lck, increased the
serine-base exchange activity at concentrations 6 1 WM [21].
3.3. Phosphatidylserine synthesis in mutants of Jurkat cells
We next examined serine-base exchange activity in J.CaM
1.6, a mutant Jurkat cell lacking p56lck activity [22] derived
from another Jurkat clone, JE6-1. Fig. 2 shows that J.CaM
1.6 incorporated 2-fold more [
3
H]serine into PtdSer than the
parental cell, JE6-1. The e¡ect of AHF (40 WM) on PtdSer
synthesis was then compared in JD, JE6-1 and JCaM 1.6.
AHF increased similarly in JD and JE6-1 but was inactive
in JCaM1.6 (Fig. 3) indicating that in the absence of p56lck
activity PtdSer synthesis is upregulated and that AHF inter-
acts speci¢cally with this protein tyrosine kinase. It is inter-
esting to note that under our experimental conditions the
PtdSer synthesizing pathway was not saturated by a 2-fold
increase since on using other compounds such as oleylamine
or stearylamine a 5-fold increase of PtdSer can be observed
[21].
3.4. The AHF e¡ect is recovered in p56lck-transfected
JCaM 1.6 cells
To determine whether the defect in p56lck was responsible
for the changes observed in the activity of the serine-base
exchange system, we restored the p56lck activity by transfec-
tion with a cDNA clone of p56lck. JCaM 1.6 cells were trans-
fected via electroporation by using p56lck cDNA included in
the mammalian expression vector pEF-BOS. Positive clones
were isolated, cultured and then cloned by limiting dilution.
As shown in Fig. 3, the enhancing e¡ect of AHF on PtdSer
synthesis was recovered in p56lck transfectants.
3.5. AHF impairs CD3-induced inhibition of PtdSer synthesis
Triggering the CD3-TCR complex with CD3 mAbs induces
a marked decrease of PtdSer synthesis [4,5]. This decrease was
previously attributed to the fact that CD3 mAbs empty endo-
plasmic reticulum Ca
2
stores, since a similar decrease of
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Table 1
E¡ect of 4-aminohydroxy£avone (AHF) on phospholipid biosynthesis.
Label Phospholipids Control AHF (40 WM)
[
3
H]Palmitic acid PtdIns-P/PtdIns-P2 2412þ 59 2704þ 211
PtdCho 3078þ 339 3246þ 68
PtdSer/PtdIns 407þ 56 400þ 73
PtdEtn 3681þ 223 3543þ 309
Neutral lipids 3521þ 70 3516þ 83
[
3
H]Choline PtdCho 1279þ 97 1176þ 60
[
3
H]Ethanolamine PtdEtn 4233þ 686 4558þ 324
Jurkat cells were labeled with either [
3
H]palmitic acid, [
3
H]choline or [
3
H]ethanolamine for 2 h in the absence (control) or presence of 40 WM AHF.
Phospholipids were extracted then separated by thin-layer chromatography and quanti¢ed with a radiochromatography scanner. Results are
expressed as cpmþS.D. (n=4).
Fig. 2. Jurkat J E6-1 cells (E) synthesize less PtdSer than J.CaM 1.6
(F), a p56lck negative mutant. The incorporation of [
3
H]serine into
PtdSer was plotted as a function of cell concentration. PtdSer syn-
thesis was measured after a 120 min time period.
Fig. 3. E¡ect of AHF in the di¡erent Jurkat clones. PtdSer synthe-
sis was monitored in both control and 40 WM AHF treated cells.
The incorporation of [
3
H]serine into PtdSer was measured after an
incubation period of 120 min in Jurkat clone D (J.D), J E6-1,
J.CaM 1.6 (lacking p56lck) and in a clone of JCAM 1.6 transfected
with p56lck cDNA (Tr). Results are expressed as %þS.D. (n=6)
vs. controls (taken as 100%).
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PtdSer synthesis is also observed with the Ca
2
-ATPase
blocker, thapsigargin. As expected, AHF was capable of
blocking the CD3-induced inhibition of PtdSer synthesis. By
contrast, the e¡ect of thapsigargin was not reversed by the
drug (Fig. 4). Since CD3-induced intracellular signaling in-
volves the activation of protein tyrosine kinases while thapsi-
gargin bypasses these early events, it appeared likely that
AHF would block the protein tyrosine kinase p56lck.
Taken together, the results presented indicate that the pro-
tein tyrosine kinase, p56lck, probably participates in the reg-
ulation of the serine-base exchange enzyme system in Jurkat
cells. Previously, we have repeatedly shown that increasing
PtdSer synthesis results in decreased interleukin-2 (IL-2) pro-
duction by activated T cells, suggesting that PtdSer plays a
major role in T cell activation. In vivo experiments also sup-
ported this conclusion [23]. We have shown that AHF inhibits
IL-2 production in Jurkat cells activated by CD3 mAb in the
presence of the phorbol ester, TPA. AHF also inhibits the
surface expression of CD25, a chain of the IL-2 receptor
and the surface expression of CD69, an early activation-in-
duced protein (unpublished results). Besides its role in T cell
activation, another important role for PtdSer in the regulation
of lymphocytes arises from the discovery that T cell apoptosis
is accompanied by the exposure of PtdSer at the cell surface
where this phospholipid serves for the recognition by macro-
phages in a way to eliminate dying cells [24^26]. Also, the
recent demonstration [27] that src tyrosine kinases bind to
membranes through electrostatic interactions with acidic
phospholipids and particularly to PtdSer indicates that this
phospholipid might play a role in the membrane targeting
of p56lck during T cell activation. Accordingly, the study of
the ¢ne regulation of PtdSer biosynthesis appears to be an
important step in the understanding of the regulation of T
cell functions.
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Fig. 4. AHF impairs CD3-induced inhibition of PtdSer synthesis.
Jurkat cells were left untreated (control) or treated with either 40
WM AHF, CD3 mAb (2 Wg/ml) or thapsigargin (Tg) 10
37
M in the
presence or absence of AHF. PtdSer synthesis was measured after
120 min. The results are the meanþS.D. from two experiments per-
formed in triplicate (n=6).
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